Akhtar Javed, Wang Zhou, Yu Che, Zhang Zhi Ping, Bi Ming Ming
Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Shandong, China.
Ann Surg Oncol. 2014 Jan;21(1):315-21. doi: 10.1245/s10434-013-3215-z. Epub 2013 Aug 22.
Prognosis of esophageal squamous cell carcinoma (ESCC) is stage-specific; however, some patients with the same stage have different survival outcomes. Clinically, it is significant to explore the biological marker to predict patient's outcome. We investigated the association between the stathmin1 gene (STMN-1) expression and the prognosis of patients who underwent Ivor-Lewis esophagectomy.
A total of 162 patients who suffered from midthoracic stage IIA ESCC and completely resected with Ivor-Lewis esophagectomy were studied for STMN-1 expression by qRT-PCR in fresh-frozen tissue and validated by immunohistochemistry in matched formalin fixed-paraffin embedded tissue samples. STMN-1 level was evaluated as a prognostic factor in ESCC. SPSS 21.0 software was used to analyze the relationship between STMN-1 expression and clinicopathological characteristics and survival probability.
The overall 3- and 5-year survival was 72.20 and 42.00 % respectively. Ninety-four patients (58.02 %) experienced disease recurrence with a disease-free interval of 21.50 ± 1.20 months. qRT-PCR result showed that STMN-1 mRNA level in patients who were alive at the end of follow-up was lower compared with patients who died during the follow-up period (p < 0.05). Immunohistochemical results showed that 94 patients had STMN-1 protein overexpression (58.02 %), patient with STMN-1 overexpression had worse survival compared with patients who had low STMN-1 expression (p = 0.00). Cox regression analysis revealed that STMN-1 protein expression and T classification are independent prognostic factors.
Even localized ESCC are potential to relapse with poor prognosis. This study demonstrates that STMN-1 level is an independent prognostic factor after Ivor-Lewis esophagectomy. In addition, assessment of STMN-1 level could improve stratification of stage IIA ESCC patients.
食管鳞状细胞癌(ESCC)的预后具有阶段特异性;然而,一些处于相同阶段的患者生存结果却有所不同。临床上,探索能够预测患者预后的生物标志物具有重要意义。我们研究了Stathmin1基因(STMN-1)表达与接受Ivor-Lewis食管切除术患者预后之间的关联。
对162例患有胸中段IIA期ESCC且接受Ivor-Lewis食管切除术并完全切除的患者,通过qRT-PCR在新鲜冷冻组织中研究STMN-1表达,并在匹配的福尔马林固定石蜡包埋组织样本中通过免疫组织化学进行验证。将STMN-1水平评估为ESCC的一个预后因素。使用SPSS 21.0软件分析STMN-1表达与临床病理特征及生存概率之间的关系。
总体3年和5年生存率分别为72.20%和42.00%。94例患者(58.02%)出现疾病复发,无病间期为21.50±1.20个月。qRT-PCR结果显示,随访结束时存活患者的STMN-1 mRNA水平低于随访期间死亡的患者(p<0.05)。免疫组织化学结果显示,94例患者存在STMN-1蛋白过表达(58.02%),STMN-1过表达的患者与STMN-1低表达的患者相比生存情况更差(p = 0.00)。Cox回归分析显示,STMN-1蛋白表达和T分类是独立的预后因素。
即使是局限性ESCC也有复发的可能且预后较差。本研究表明,STMN-1水平是Ivor-Lewis食管切除术后的一个独立预后因素。此外,评估STMN-1水平可改善IIA期ESCC患者的分层。